BRCA1 and neoplasm: Rucaparib was also approved by the FDA for patients with deleterious BRCA1 or BRCA2 mutation (germline and/or somatic)‐associated mCRPC who have been treated with androgen receptor‐directed therapy and a taxane‐based chemotherapy based on the tumour testing findings of the TRITON2 study [34].